A ‘whistleblower,’ not Trump officials, delayed funding for molnupiravir. When Merck and Ridgeback Biotherapeutics announced on Oct. 1 that their new antiviral pill reduced Covid hospitalizations by roughly half, some in the media blamed Donald Trump. An Axios headline: “Before Merck backed COVID antiviral, Trump admin turned it down.” In